EFACTS
European Friedreich's Ataxia Consortium for Translational Studies
| Coordinatore | UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Sito del progetto | http://www.e-facts.eu/ |
| Totale costo | 7˙934˙618 € |
| EC contributo | 5˙983˙379 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-05-01 - 2015-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
BE (BRUXELLES) | coordinator | 1˙144˙580.00 |
| 2 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 727˙000.00 |
| 3 |
BRUNEL UNIVERSITY
Organization address
address: Kingston Lane contact info |
UK (UXBRIDGE) | participant | 665˙912.00 |
| 4 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 561˙508.00 |
| 5 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 559˙000.00 |
| 6 |
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE
Organization address
address: Rue Laurent Fries 1 contact info |
FR (ILLKIRCH GRAFFENSTADEN) | participant | 530˙500.00 |
| 7 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 470˙980.00 |
| 8 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 398˙000.00 |
| 9 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 373˙184.00 |
| 10 |
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
IT (MILANO) | participant | 216˙000.00 |
| 11 |
REPLIGEN CORPORATION
Organization address
address: SEYON STREET 41 contact info |
US (WALYHAM) | participant | 115˙000.00 |
| 12 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 102˙915.00 |
| 13 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 64˙800.00 |
| 14 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 54˙000.00 |
| 15 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'EFACTS (the European Friedreich’s Ataxia Consortium for Translational Studies) assembles a body of expertise to adopt a translational research strategy for the rare autosomal recessive neurological disease, Friedreich’s ataxia (FRDA). FRDA is a severely debilitating disease that leads to loss of the ability to walk and dependency for all activities. Some patients have cardiomyopathy that can cause premature death, visual and auditory loss, kyphoscoliosis, pes cavus, diabetes. Onset is usually in childhood, but it may vary from infancy to adulthood. FRDA involves child health and ageing aspects. FRDA affected individuals and clinical specialists are dispersed. This is a hindrance for patients to receive the care they need, and for clinicians and researchers to make progress. EFACTS has been created to move past this limitation. EFACTS strongly believes that, 12 years after European researchers discovered the FRDA gene, frataxin, when new treatments for FRDA are being developed, the time is ripe to invest in FRDA research in a concerted Europe-wide fashion. EFACTS gathers the critical mass of researchers and clinicians to exploit the patient base, research reagents and knowledge for progress. This comes when IT can act as a crucial support for collaborative work in collecting patient data and material, making it available to leading researchers for advanced analysis, research and drug development. This project proposal has the following scientific and technological objectives: 1. Comprehensively populate a European FRDA database, linked to a bio bank; 2. Define a panel of clinical assessment tools; 3. Build on the knowledge base of frataxin structure and function; 4. Build on the knowledge base of the pathogenic cascade; 5. Build on the knowledge base of epigenetic mechanisms of frataxin silencing; 6. Develop new cellular and animal models for the study of FRDA; 7. Identify FRDA biomarkers; 8. Identify genetic modifiers of FRDA; 9. Develop therapeutics for FRDA.'
Introduzione (Teaser)
European researchers are joining forces to dissect the mechanisms of Friedreich's ataxia (FRDA) and provide new therapeutic solutions. By combining mechanistic, clinical and therapeutic research, the EFACTS consortium hopes to improve existing disease management options.